# CureGN-Penn PCC

> **NIH NIH U01** · UNIVERSITY OF PENNSYLVANIA · 2024 · $925,000

## Abstract

Project Summary/Abstract
 Primary glomerular diseases, including minimal change disease (MCD), focal segmental
glomerulosclerosis (FSGS), immunoglobulin A nephropathy (IgAN), and membranous nephropathy (MN), are
associated with significant morbidity and mortality in both adults and children. The Cure Glomerulonephropathy
(CureGN) study launched in 2013 to address critical knowledge gaps in the disease pathogenesis, natural
history, and response to therapy of these heterogeneous disorders. It is a study of unprecedented size and
remarkable depth, built by a unique collaborative interdisciplinary community. The international consortium
includes researchers with diverse expertise, affected patients and advocacy groups, the biopharmaceutical
industry, and federal funding agencies. CureGN has successfully recruited a diverse cohort of nearly 2800
adult and pediatric participants with MCD, FSGS, IgAN and MN from more than 60 clinical study sites into a
prospective, longitudinal, observational cohort study. Biospecimens, clinical data, and patient reported
outcomes are collected to enable high-quality clinical, mechanistic, and translational investigations. This
foundational work is being conducted by a well-functioning collaborative group including the Data Coordinating
Center (at the University of Michigan, Northwestern University and Cleveland Clinic) and four Participating
Clinical Centers (managed at the University of Pennsylvania, Columbia University, University of North Carolina,
and the Pediatric Nephrology Research Consortium). CureGN will pave the way for personalized care in
glomerular disease by disentangling the heterogeneity of disorders that are etiologically diverse but currently
grouped into only four diagnoses.
 In CureGN’s third study phase, we propose to maintain and enhance the CureGN Consortium
infrastructure and ancillary study program to accelerate patient-relevant glomerular disease research. We will
continue our core observational study, enrolling additional participants in a recruit-to-replace strategy to
maintain an active cohort of 2000 participants with high quality clinical data and biomaterials. We will
implement state of the art data collection tools including remote data and biospecimen collection, new
biospecimen types, and use of mobile devices for patient facing engagement and medical record linkages.
Mature scientific working groups, committees and ancillary infrastructure will continue to support a core and
ancillary study program to achieve the scientific goals of CureGN. We will continue outreach to the scientific
community by expanding CureGN’s role as an outstanding training vehicle for the next generation of
glomerular disease researchers and attracting cutting-edge, established scientists to glomerular disease
through opportunity pool grants, collaborations with patient advocacy groups and professional societies,
training workshops and support of ancillary studies from academic and industry partners. Through ...

## Key facts

- **NIH application ID:** 10972967
- **Project number:** 2U01DK100846-12
- **Recipient organization:** UNIVERSITY OF PENNSYLVANIA
- **Principal Investigator:** LAWRENCE B. HOLZMAN
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $925,000
- **Award type:** 2
- **Project period:** 2013-09-16 → 2029-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10972967

## Citation

> US National Institutes of Health, RePORTER application 10972967, CureGN-Penn PCC (2U01DK100846-12). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10972967. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*